The development of antimicrobials for the treatment of resistant fungal and bacterial infections - OTA
Active Definitive Contract Awarded Last action
- Contract number
- 75A50124C00033
- Awardee
-
Basilea Pharmaceutica International Ltd, Allschwil UEI UA43HWRNXFS3
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $122,501,232
Award facts
- Opportunity
-
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Pre-Solicitation · BAA18100SOL00003 · Posted Oct 16, 2017
- Contract value 49% obligated
-
- $122,501,232.00 Current, with exercised options
- $252,093,994.00 Potential, with all options
- Completion date 18% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Sharing
- Place of performance
- Switzerland
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $30,000,000 | |
| Supplemental Agreement for work within scope | $24,706,190 | |
| Exercise an Option | $39,113,520 | |
| Other Administrative Action | $0 | |
| Original award | $28,681,522 |
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a definitive cost-sharing contract to Basilea Pharmaceutica International Ltd, Allschwil for the development of antimicrobials to treat resistant fungal and bacterial infections, with a ceiling value of $252.1 million and an ultimate completion date of December 31, 2035.
This modification exercises Option 3 CLIN0004 and updates the statement of work dated June 10, 2026. The contract originated from a Biomedical Advanced Research and Development Authority broad agency announcement posted in October 2017, which sought advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats. Work is performed in Switzerland. The contract supports development of novel antibiotics targeting multidrug-resistant gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and multidrug-resistant Pseudomonas aeruginosa, with focus on new antibiotic classes targeting the lipopolysaccharide transport system and inhibitors of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, an enzyme not targeted by current antibiotics.
Quick answers
Who was awarded contract 75A50124C00033?
75A50124C00033 was awarded to Basilea Pharmaceutica International Ltd, Allschwil by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2024.
How much is contract 75A50124C00033 worth?
The government has obligated $122,501,232 on 75A50124C00033. Its potential value, with all options, is $252,093,994.
Was contract 75A50124C00033 competed?
The extent of competition for 75A50124C00033 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award